• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Shareholders of Global Cord Blood Corporation Are Reminded to Comply with the Rules of Conduct When Attending the Extraordinary General Meeting and Exercising Their Voting Rights

    6/15/22 7:38:00 AM ET
    $CO
    Managed Health Care
    Health Care
    Get the next $CO alert in real time by email

    Blue Ocean Structure Investment Company Ltd.,("Blue Ocean") together with shareholders representing no less than 75% of the outstanding shares of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO) have called an Extraordinary General Meeting of Shareholders ("EGM" or the "Meeting") as allowed by the Company's Articles. The EGM will be held at DLA Piper LLP (US), 1251 Avenue of the Americas, New York, NY 10020-1104, United States of America, on 16 June, 2022 at 9:00 a.m. Eastern Time.

    To ensure fairness to all participants and in the interest of an orderly and constructive Meeting, Blue Ocean has established Rules of Conduct (the "Rules"). The Rules of Conduct will be enforced. Participants who fail to comply with these Rules will be removed from the Meeting.

    The Rules of Conduct includes, but not limited to:

    1. Upon entering the building of DLA Piper LLP (US) office, attendees must register with building security using a valid personal identification. Inform building security that they are attending the Meeting at the DLA Piper offices, and wait to be escorted to the Meeting registration station in DLA Piper's offices.
    2. Once at the Meeting registration station, all attendees must register at the desk before entering the Meeting room. Only a verified shareholder or director of the Company will be admitted to the Meeting, unless otherwise determined by Blue Ocean. All attendees must present valid personal identification and proof of full vaccination against COVID-19 (including at least one booster) or proof of a negative antigen test obtained within 24 hours of the Meeting start time. Shareholders and proxy holders must present evidence of ownership as of the record date in a form satisfactory to Blue Ocean (in its sole discretion).
    3. The Meeting will begin promptly at 9:00 a.m. ET, at which point no additional participants will be admitted to the Meeting room. Accordingly, participants must have successfully completed all registration steps prior to 9:00 a.m. ET.
    4. The use of audio or video recording equipment and the taking of photographs are strictly prohibited. Cell phones, tablets and similar electronic devices must be turned off prior to entering the Meeting room.
    5. The Meeting will follow the Agenda provided to all shareholders upon entering the Meeting.
    6. Only shareholders of record as of May 18, 2022 or their duly authorized proxy holders are entitled to vote at or participate in the Meeting. Shareholders who hold their shares in street name through a bank, broker or other nominee will not be able to vote or participate in the Meeting unless they have a legal proxy from their bank, broker or other nominee.
    7. Shareholders do not need to vote at this Meeting if they have already voted by proxy. If any shareholders wish to change their votes or have yet to vote, please request a ballot and turn in the completed ballot before the closing of polls.
    8. Only Company shareholders are permitted to ask questions during the Meeting. All questions and comments must be directed to the chairperson of the Meeting, after the chairperson opens the floor for questions and recognizes their requests.
    9. For attendees who wish to be recognized, please raise their hands. When recognized by the chairperson, the attendee is required to state his or her full name and indicate whether he or she is a shareholder or a proxy holder. Please permit each speaker to conclude his or her remarks without interruption. The chairperson will warn speakers if they are out of order and stop any discussions that include derogatory references that are not in good taste or related to personal grievances.
    10. Shareholders' questions or comments should be strictly confined to the matters under consideration at the Meeting.
    11. Each speaker is limited to no more than 2 questions or comments, each of which must be no more than 5 minutes in length. Please allow other speakers to be recognized before asking to be recognized again.
    12. The chairperson of the Meeting shall have the authority necessary to preside over the Meeting and may make any and all determinations with respect to the conduct of the Meeting and procedures to be followed during the Meeting.

    For more details of the Rules of Conduct, please refer to Exhibit A of the 13D filing: https://www.sec.gov/Archives/edgar/data/0001729271/000110465922071181/0001104659-22-071181-index.htm

    Blue Ocean would like to thank all shareholders in advance for their support and to comply with the Rules of Conduct for the upcoming EGM. In addition, Blue Ocean urges all shareholders of the Company to vote FOR each of the resolutions of the EGM via the BLUE proxy card they have received or through their brokers or at the EGM.

    Shareholders who have any questions or need assistance to have their shares voted prior or at the EGM, please contact Morrow Sodali LLC, our proxy solicitor assisting us in connection with the EGM, toll-free in North America at (800) 662-5200 or at + 1 203 658-9400 or by email to [email protected].

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005618/en/

    Get the next $CO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GLOBAL CORD BLOOD CORPORATION ANNOUNCES FAILURE TO FILE INTERIM FINANCIALS

    GEORGE TOWN, Cayman Islands and HONG KONG, April 13, 2023 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), a provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services in China, announced that it received a notice (the "Notice") on April 3, 2023 from the New York Stock Exchange ("NYSE") with respect to its failure to timely file on Form 6-K its semi-annual financials for the six-month period ended September 30, 2022 (the "Interim Financials") as required by NYSE Listing Standard 203.03. As previously announced, on September 22, 2022, the Grand Court of the Cayman Islands issued an order (the "Order") appoi

    4/13/23 3:08:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

    Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the "Joint Provisional Liquidators"). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Oce

    9/26/22 4:07:00 PM ET
    $CO
    Managed Health Care
    Health Care

    The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

    Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JP

    9/23/22 1:52:00 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    SEC Filings

    View All

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    2/12/24 5:06:46 PM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    12/4/23 5:15:19 PM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    9/29/23 4:33:27 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Leadership Updates

    Live Leadership Updates

    View All

    Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

    Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the "Joint Provisional Liquidators"). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Oce

    9/26/22 4:07:00 PM ET
    $CO
    Managed Health Care
    Health Care

    The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

    Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JP

    9/23/22 1:52:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting

    HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual General Meeting of shareholders, held on December 7, 2021, in Hong Kong S.A.R., China. At the Annual General Meeting, the Company's shareholders ratified the re-appointment of KPMG Huazhen LLP as independent auditors of the Company for the financial year ending March 31, 2022, and authorized any duly formed committee of the directors to fix the remuneration of the independent auditors; and re-elected Ms.

    12/7/21 8:32:00 AM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Global Cord Blood Corporation (Amendment)

    SC 13G/A - Global Cord Blood Corp (0001467808) (Subject)

    2/14/24 10:15:21 AM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form SC 13G filed by Global Cord Blood Corporation

    SC 13G - Global Cord Blood Corp (0001467808) (Subject)

    2/14/23 10:23:43 AM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form SC 13G/A filed by Global Cord Blood Corporation (Amendment)

    SC 13G/A - Global Cord Blood Corp (0001467808) (Subject)

    2/3/23 2:38:38 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Financials

    Live finance-specific insights

    View All

    Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022

    Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY to RMB153.9 Million ($24.3 Million) HONG KONG, July 5, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended March 31, 2022.

    7/5/22 4:16:00 PM ET
    $CO
    $INCY
    Managed Health Care
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022

    Added 18,985 New Subscribers in 3Q22Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million)         Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million)Operating Income Up 20.8% YoY to RMB149.7 Million ($23.5 Million) Non-GAAP Operating Income Up 18.6% YoY to RMB161.6 Million ($25.4 Million)Conference Call to be Held on March 1, 2022, at 8:00 a.m. ET HONG KONG, Feb. 28, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine month

    2/28/22 4:16:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2022 Financial Results

    HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release its financial results for the third quarter and first nine months of fiscal 2022 on Monday, February 28, 2022, after the U.S. market close.  The Company will host a conference call at 8:00 a.m. ET on Tuesday, March 1, 2022 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session. Interested parties can access the audio webcast through

    2/23/22 7:00:00 AM ET
    $CO
    Managed Health Care
    Health Care